T & D Diagnostics – Trademark Portfolio
Entity Type: 99
T & D Diagnostics holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include CENTUS, SIENNA, and SIERRA. The owner is based in Dartmouth, Nova Scotia.
219 Waverley Road, Suite 201
Dartmouth, Nova Scotia B2X2C3 , CA
Showing of trademarks Trademarks
Trademark Classifications
T & D Diagnostics's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does T & D Diagnostics have?
T & D Diagnostics has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 abandoned.
What trademark classes does T & D Diagnostics file in?
T & D Diagnostics files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are T & D Diagnostics's most well-known trademarks?
T & D Diagnostics's registered trademark portfolio includes well-known marks such as CENTUS, SIENNA, and SIERRA. These are among 4 currently registered trademarks in the portfolio.
What is T & D Diagnostics's trademark registration success rate?
T & D Diagnostics has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.